IFN-γ for Friedreich ataxia: present evidence

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Campuzano V, Montermini L, Moltò MD et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254), 1423–1427 (1996).
  Medline CASGoogle Scholar
• 2 Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch. Neurol. 59(5), 743–747 (2002).
  MedlineGoogle Scholar
• 3 Wilson RB. Therapeutic developments in Friedreich ataxia. J. Child Neurol. 27(9), 1212–1216 (2012).
  MedlineGoogle Scholar
• 4 Lynch DR, Farmer JM, Tsou AY et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology 66(11), 1711–1716 (2006). • Describes the neurological examination (Friedreich Ataxia Rating Scale) and performance measures used in clinical assessment of Friedreich ataxia (FRDA) patients and which provide the basis of outcome measures in the open-label pilot study and ongoing Phase III study of IFN-γ in FRDA.
  Medline CASGoogle Scholar
• 5 Bidichandani SI, Ashizawa T, Patel PI. Atypical Friedreich ataxia caused by compound heterozygosity for a novel Missense mutation and the GAA triplet-repeat expansion. Am. J. Hum. Genet. 60(5), 1251–1256 (1997).
  Medline CASGoogle Scholar
• 6 Seyer L, Greeley N, Foerster D et al. Open label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol. Scand. 132(1), 7–15 (2014). •• Publication of the results of the open-label pilot study of IFN-γ in children with FRDA.
  MedlineGoogle Scholar
• 7 Guillon B, Bulteau AL, Wattenhofer-Donzé M et al. Frataxin deficiency causes upregulation of mitochondrial Lon and ClpP proteases and severe loss of mitochondrial Fe-S proteins. FEBS J. 276(4), 1036–1047 (2009).
  Medline CASGoogle Scholar
• 8 Stemmler TL, Lesuisse E, Pain D, Dancis A. Frataxin and mitochondrial Fe-S cluster biogenesis. J. Biol. Chem. 285(35), 26737–26743 (2010).
  Medline CASGoogle Scholar
• 9 Adinolfi S, Iannuzzi C, Prischi F et al. Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS. Nat. Struct. Mol. Biol. 16(4), 390–396 (2009).
  Medline CASGoogle Scholar
• 10 Yoon T, Cowan JA. Iron-sulfur cluster biosynthesis: characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J. Am. Chem. Soc. 125(20), 6078–6084 (2003).
  Medline CASGoogle Scholar
• 11 Babcock M, de Silva D, Oaks R et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276(5319), 1709–1712 (1997).
  Medline CASGoogle Scholar
• 12 Adamec J, Rusnak F, Owen WG et al. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am. J. Hum. Genet. 67(3), 549–562 (2000).
  Medline CASGoogle Scholar
• 13 Rotig A, de Lonlay P, Chretien D et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17(2), 215–217 (1997).
  Medline CASGoogle Scholar
• 14 Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci. 303(1–2), 1–12 (2011).
  Medline CASGoogle Scholar
• 15 Deutsch EC, Santani AB, Perlman SL et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol. Genet. Metab. 101(2–3), 238–245 (2010).
  Medline CASGoogle Scholar
• 16 Lynch DR, Perlman SL, Meier T. A Phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 67(8), 941–947 (2010).
  MedlineGoogle Scholar
• 17 Lynch DR, Willi SM, Wilson RB et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov. Disord. 27(8), 1026–1033 (2012).
  Medline CASGoogle Scholar
• 18 Myers L, Farmer JM, Wilson RB et al. Antioxidant use in Friedreich ataxia. J. Neurol. Sci. 267(1–2), 174–176 (2008).
  Medline CASGoogle Scholar
• 19 Kearney M, Orrell RW, Fahey M, Pandolfo M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst. Rev. 18, 4 (2012).
  Google Scholar
• 20 Pandolfo M, Arpa J, Delatycki MB et al. Deferiprone in Friedreich ataxia: a 6 month randomized controlled trial. Ann. Neurol. 76(4), 509–521 (2014).
  Medline CASGoogle Scholar
• 21 Arpa J, Sanz-Gallego I, Rodríguez-de-Rivera FJ et al. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia – open-label trial. Acta Neurol Scand. 129(1), 32–40 (2014).
  Medline CASGoogle Scholar
• 22 Velasco-Sánchez D, Aracil A, Montero R et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10(1), 1–8 (2011).
  Medline CASGoogle Scholar
• 23 Sanz-Gallego I, Torres-Aleman I, Arpa J. IGF-1 in Friedreich's Ataxia proof-of-concept trial. Cerebellum Ataxias 1, 10 (2014).
  MedlineGoogle Scholar
• 24 Boesch S, Nachbauer W, Mariotti C et al. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia. Mov. Disord. 29(7), 935–939 (2014).
  Medline CASGoogle Scholar
• 25 Mariotti C, Fancellu R, Caldarazzo S et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov. Disord. 27(3), 446–449 (2012).
  Medline CASGoogle Scholar
• 26 Rai M, Soragni E, Jenssen K et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3(4), e1958 (2008).
  MedlineGoogle Scholar
• 27 Sandi C, Pinto RM, Al-Mahdawi S et al. Prolonged treatment with pimelic O-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 42(3), 496–505 (2011).
  Medline CASGoogle Scholar
• 28 Beconi M, Aziz O, Matthews K et al. Oral Administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS ONE 7(9), e44498 (2012).
  Medline CASGoogle Scholar
• 29 Isaacs CJ, Shinnick JE, Schadt K, Lynch DR, Lin KY. Prospects of gene and cell therapy for managing cardiac complications in Friedreich ataxia. Expert Opin. Orphan Drugs doi:10.1517/21678707.2015.1083854 (2015) (Epub ahead of print).
  Google Scholar
• 30 Tomassini B, Arcuri G, Fortuni S et al. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum. Mol. Genet. 21(13), 2855–2861 (2012). •• Describes the observed effects that IFN had on upregulation of frataxin a variety of cell types, including cells derived from FRDA patients. Also describes observed improvement of symptoms in an FRDA mouse model treated with IFN.
  Medline CASGoogle Scholar
• 31 Clinical Trials Database: NCT02035020. https://clinicaltrials.gov/ct2/show/NCT02035020. •• Refer to for additional details about the current Phase IIa study in FRDA in Italy.
  Google Scholar
• 32 Clinical Trials Database: NCT02415127. https://clinicaltrials.gov/ct2/show/NCT02415127. •• Refer to for additional details about the current Phase III study in FRDA in the USA.
  Google Scholar
• 33 ACTIMMUNE (interferon gamma-1b) full prescribing information. Vidara Therapeutics Research Ltd, Roswell, GA, USA (2013). •• Provides the current indication, safety data and pharmacokinetics of ACTIMMUNE®).
  Google Scholar
• 34 Bitran JD, Green M, Perry M, Hollis DR, Herndon JE 2nd. A Phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. Am. J. Clin. Oncol. 18(1), 67–70 (1995).
  Medline CASGoogle Scholar
• 35 Peprotech: Manufacturer of Quality Cytokine Products: Recombinant Human IFN-γ. Peprotech, Rocky Hill, NJ, USA (2015). www.peprotech.com/en-US/Pages/Product/Recombinant_Human_IFN-γ/300–302.
  Google Scholar
• 36 Young HA, Bream JH. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top. Microbiol. Immunol. 316, 97–117 (2007).
  Medline CASGoogle Scholar
• 37 Ganz T. Iron in innate immunity: starve the invaders. Curr. Opin. Immunol. 21(1), 63–67 (2009).
  Medline CASGoogle Scholar
• 38 Nairz M, Schroll A, Sonnweber T, Weiss G. The struggle for iron – a metal at the host-pathogen interface. Cell Microbiol. 12(12), 1691–1702 (2010).
  Medline CASGoogle Scholar
• 39 Collins HL. Withholding iron as a cellular defense mechanism – friend or foe? Eur. J. Immunol. 38, 1803–1806 (2008).
  Medline CASGoogle Scholar
• 40 Byrd TF, Horwitz MA. Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon γ. J. Clin. Invest. 91, 969–976 (1993).
  Medline CASGoogle Scholar
• 41 Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG, Swaak AJ. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur. J. Clin. Invest. 28, 520–527 (1998).
  Medline CASGoogle Scholar
• 42 Van Zandt KE, Sow FB, Florence WC et al. The iron export protein ferroportin 1 is differentially expressed in mouse macrophage populations and is present in the mycobacterial-containing phagosome. J. Leukoc. Biol. 84(3), 689–700 (2008).
  Medline CASGoogle Scholar
• 43 Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J. Leukoc. Biol. 82(4), 934–945 (2007).
  Medline CASGoogle Scholar
• 44 Kim S, Ponka P. Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2. J. Biol. Chem. 275(9), 6220–6226 (2000).
  Medline CASGoogle Scholar
• 45 Alter-Koltunoff M, Goren S, Nousbeck J et al. Innate immunity to intraphagosomal pathogens is mediated by interferon regulatory factor 8 (IRF-8) that stimulates the expression of macrophage-specific Nramp1 through antagonizing repression by c-Myc. J. Biol. Chem. 283(5), 2724–2733 (2008).
  Medline CASGoogle Scholar
• 46 Wilson RB, Lynch DR, Fischbeck KH. Normal serum iron and ferritin concentrations in patients with Friedreich's ataxia. Ann. Neurol. 44(1), 132–134 (1998).
  Medline CASGoogle Scholar
• 47 Wilson RB, Lynch DR, Farmer JM, Brooks DG, Fischbeck KH. Increased serum transferrin receptor concentrations in Friedreich ataxia. Ann. Neurol. 47, 659–661 (2000).
  Medline CASGoogle Scholar
• 48 Popko B, Corbin JG, Baerwald KD, Dupree J, Garcia AM. The effects of interferon-gamma on the central nervous system. Mol. Neurobiol. 14(1–2), 19–35 (1997).
  Medline CASGoogle Scholar
• 49 Too LK, Ball HJ, McGregor IS, Hunt NH. The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumococcal meningitis. Brain Behav. Immun. 40, 252–268 (2014).
  Medline CASGoogle Scholar
• 50 Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J. Rheumatol. 23(4), 654–658 (1996).
  Medline CASGoogle Scholar